Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-26-001898
Filing Date
2026-01-12
Accepted
2026-01-12 18:52:52
Documents
1
Period of Report
2026-01-08

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1768261959.html 4  
1 FORM 4 wk-form4_1768261959.xml 4 3986
  Complete submission text file 0001628280-26-001898.txt   5485
Mailing Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465
Business Address 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465 617-344-4190
Acumen Pharmaceuticals, Inc. (Issuer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O TELA BIO, INC. 1 GREAT VALLEY PARKWAY, SUITE 24 MALVERN PA 19355
Business Address
Zuga Matt (Reporting) CIK: 0001790214 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40551 | Film No.: 26528071